OCT 22, 2019 10:34 PM PDT

Using senolytics to treat cancer

New research published in Nature Metabolism proposes using an already existing drug – a cardiac glycoside called ouabain – as a senolytic to kill off damaged aging or cancerous cells. Senolytics are a class of drugs that are capable of selectively killing senescent cells, or cells that have reached their natural aging process. Although senescence is normal, previous studies have shown that senescent cells can contribute to the spread and growth of cancer tumors.

While past research has identified some senolytics with potential anti-cancer properties, those tested up until now have also had serious side effects. However, the researchers behind the new study believe that ouabain may offer a safer alternative broad-spectrum senolytic, capable of targeting a varied array of aging cells. The research team hails from the MRC London Institute of Medical Sciences in the United Kingdom.

Senior author Professor Jesús Gil commented on the potential of ouabain, saying "These drugs are already used in the clinic, so they could be repurposed to treat a long list of diseases, including cancer. This is something we are keen to explore with our clinical collaborators. Moreover, many patients are being treated with digoxin, and an epidemiologist could look retrospectively and ask the question of whether those patients who were treated with digoxin are doing better than those who weren't."

Digoxin is another type of cardiac glycoside and is in the same class of drugs as ouabain. These drugs are usually prescribed to treat cardiac arrhythmias and atrial fibrillation; however, when the researchers experimented with them to see how they affect healthy and senescent cells, they discovered that ouabain, in particular, is capable of selectively killing aging cells.

In the study, which was conducted in aging mice with precancerous lesions in the liver and after radiotherapy, the team found that ouabain was successful in killing cells senescent from cancer as well as those senescent from exposure to radiotherapy or chemotherapy.

The authors say that future studies should continue to consider the potential of cardiac glycosides as senolytics in cancer treatments. They hope to continue their investigations in this field.

Sources: Nature Metabolism, Medical News Today

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
NOV 18, 2019
Cancer
NOV 18, 2019
Handheld device detects skin cancer
I can’t be the only one who has ever looked at a suspicious freckle and wondered, “Could this be skin cancer?” Of course, when 9,500 Amer...
NOV 18, 2019
Cancer
NOV 18, 2019
One third of women don't take advantage of free cancer screenings
Have you ever received a cancer screening? If you haven’t, you’re not alone. New research from King's College London and Queen Mary Univers...
NOV 18, 2019
Drug Discovery & Development
NOV 18, 2019
Promising Drug for Prostate Cancer
Using high-throughput screening methods, cancer researchers from the UK have identified some promising drug candidates to test thousands of molecules. Spec...
NOV 18, 2019
Drug Discovery & Development
NOV 18, 2019
Compound in Daffodils Can Help Fight Cancer
Preventing the growth of tumors presents a challenge for scientists in finding a cure to cancer. Now however, researchers from the University Libre de Brux...
NOV 18, 2019
Cell & Molecular Biology
NOV 18, 2019
New Type of CAR T-Cell Therapy Headed for Clinical Trials
Scientists have been trying to use the immune system in cancer patients' bodies to fight cancer....
NOV 18, 2019
Cancer
NOV 18, 2019
Specific gut bacteria linked to bowel cancer
New research suggests that the presence of a certain kind of gut bacteria can increase the risk of bowel cancer by as much as 15%. The research is importan...
Loading Comments...